Aparna Kamat, MD

  • Houston Methodist gynecologic oncologist
  • Gynecologic oncologist, Houston Methodist Cancer Center
  • Division of gynecologic oncology chief, Houston Methodist Hospital

Aparna Kamat, MD

Areas of Expertise

  • Complex pelvic disease
  • Gynecologic cancer (ovarian, cervical, endometrial
  • Gynecologic surgery


American Board of Obstetrics and Gynecology
Gynecological Oncology
Seth GS Medical College-Bombay, India | 1994
West Virginia University | 2001
West Virginia University | 1997
Gynecologic Oncology- Houston | 2004


Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL
Lyons, YA, Kamat, AA, Zhou, H, Mody, DR, Schwartz, MR, Hobday, C & Ge, Y 2015, , Cancer cytopathology, vol. 123, no. 7, pp. 435-442. https://doi.org/10.1002/cncy.21549

Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Gillet, JP, Calcagno, AM, Varma, S, Davidson, B, Elstrand, MB, Ganapathi, R, Kamat, AA, Sood, AK, Ambudkar, SV, Seiden, MV, Rueda, BR & Gottesman, MM 2012, , Clinical Cancer Research, vol. 18, no. 11, pp. 3197-3206. https://doi.org/10.1158/1078-0432.CCR-12-0056

Ovarian cancer
Bhosale, P, Kamat, A & Eifel, PJ 2012, . in Oncologic Imaging: A Multidisciplinary Approach. Elsevier Health Sciences, pp. 455-478. https://doi.org/10.1016/B978-1-4377-2232-1.00026-7

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
Coleman, RL, Duska, LR, Ramirez, PT, Heymach, JV, Kamat, AA, Modesitt, SC, Schmeler, KM, Iyer, RB, Garcia, ME, Miller, DL, Jackson, EF, Ng, CS, Kundra, V, Jaffe, R & Sood, AK 2011, , The Lancet Oncology, vol. 12, no. 12, pp. 1109-1117. https://doi.org/10.1016/S1470-2045(11)70244-3

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors
Liggett, TE, Melnikov, A, Yi, Q, Replogle, C, Hu, W, Rotmensch, J, Kamat, A, Sood, AK & Levenson, V 2011, , Gynecologic oncology, vol. 120, no. 1, pp. 113-120. https://doi.org/10.1016/j.ygyno.2010.09.019

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer
Merritt, WM, Kamat, AA, Hwang, JY, Bottsford-Miller, J, Lu, C, Lin, YG, Coffey, D, Spannuth, W, Nugent, E, Han, LY, Landen, CN, Nick, AM, Stone, RL, Coffman, KT, Bruckheimer, E, Broaddus, R, Gershenson, DM, Coleman, RL & Sood, AK 2010, , Cancer Biology and Therapy, vol. 10, no. 12, pp. 1306-1314. https://doi.org/10.4161/cbt.10.12.13582

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
Sood, AK, Armaiz-Pena, GN, Halder, J, Nick, AM, Stone, RL, Hu, W, Carroll, AR, Spannuth, WA, Deavers, MT, Allen, JK, Han, LY, Kamat, AA, Shahzad, MMK, McIntyre, BW, Diaz-Montero, CM, Jennings, NB, Lin, YG, Merritt, WM, DeGeest, K, Vivas-Mejia, PE, Lopez-Berestein, G, Schaller, MD, Cole, SW & Lutgendorf, SK 2010, , Journal of Clinical Investigation, vol. 120, no. 5, pp. 1515-1523. https://doi.org/10.1172/JCI40802

Plasma cell-free DNA in ovarian cancer: An independent prognostic biomarker
Kamat, AA, Baldwin, M, Urbauer, D, Dang, D, Han, LY, Godwin, A, Karlan, BY, Simpson, JL, Gershenson, DM, Coleman, RL, Bischoff, FZ & Sood, AK 2010, , Cancer, vol. 116, no. 8, pp. 1918-1925. https://doi.org/10.1002/cncr.24997

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer
Merritt, WM, Nick, AM, Carroll, AR, Lu, C, Matsuo, K, Dumble, M, Jennings, N, Zhang, S, Lin, YG, Spannuth, WA, Kamat, AA, Stone, RL, Shahzad, MMK, Coleman, RL, Kumar, R & Sood, AK 2010, , Molecular Cancer Therapeutics, vol. 9, no. 4, pp. 985-995. https://doi.org/10.1158/1535-7163.MCT-09-0967

Frequent downregulation of miR-34 family in human ovarian cancers
Corney, DC, Hwang, CI, Matoso, A, Vogt, M, Flesken-Nikitin, A, Godwin, AK, Kamat, AA, Sood, AK, Ellenson, LH, Hermeking, H & Nikitin, AY 2010, Clinical Cancer Research, vol. 16, no. 4, pp. 1119-1128. https://doi.org/10.1158/1078-0432.CCR-09-2642

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
Merritt, WM, Danes, CG, Shahzad, MMK, Lin, YG, Kamat, AA, Han, LY, Spannuth, WA, Nick, AM, Mangala, LS, Stone, RL, Hye, SK, Gershenson, DM, Jaffe, RB, Coleman, RL, Chandra, J & Sood, AK 2009, , Cancer Biology and Therapy, vol. 8, no. 16, pp. 1596-1603. https://doi.org/10.4161/cbt.8.16.9004

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer
Kamat, AA, Coffey, D, Merritt, WM, Nugent, E, Urbauer, D, Lin, YG, Edwards, C, Broaddus, R, Coleman, RL & Sood, AK 2009, Cancer, vol. 115, no. 12, pp. 2684-2692. https://doi.org/10.1002/cncr.24335

Functional significance of VEGFR-2 on ovarian cancer cells
Spannuth, WA, Nick, AM, Jennings, NB, Armaiz-Pena, GN, Mangala, LS, Danes, CG, Lin, YG, Merritt, WM, Thaker, PH, Kamat, AA, Han, LY, Tonra, JR, Coleman, RL, Ellis, LM & Sood, AK 2009, International Journal of Cancer, vol. 124, no. 5, pp. 1045-1053. https://doi.org/10.1002/ijc.24028

Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox
Kamat, AA & Coleman, RL 2009, , Cancer Biology and Therapy, vol. 8, no. 1, pp. 18-20. https://doi.org/10.4161/cbt.8.1.7520

Dicer, Drosha, and outcomes in patients with ovarian cancer
Merritt, WM, Lin, YG, Han, LY, Kamat, AA, Spannuth, WA, Schmandt, R, Urbauer, D, Pennacchio, LA, Cheng, JF, Nick, AM, Deavers, MT, Mourad-Zeidan, A, Wang, H, Mueller, P, Lenburg, ME, Gray, JW, Mok, S, Birrer, MJ, Lopez-Berestein, G, Coleman, RL, Bar-Eli, M & Sood, AK 2008, , New England Journal of Medicine, vol. 359, no. 25, pp. 2641-2650. https://doi.org/10.1056/NEJMoa0803785

Tumor-selective response to antibody-mediated targeting of avß3 integrin in ovarian cancer
Landen, CN, Kim, TJ, Lin, YG, Merritt, WM, Kamat, AA, Han, LY, Spannuth, WA, Nick, AM, Jennnings, NB, Kinch, MS, Tice, D & Sood, AK 2008, , Neoplasia, vol. 10, no. 11, pp. 1259-1267. https://doi.org/10.1593/neo.08740

Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth
Lin, YG, Immaneni, A, Merritt, WM, Mangala, LS, Kim, SW, Shahzad, MMK, Tsang, YTM, Armaiz-Pena, GN, Lu, C, Kamat, AA, Han, LY, Spannuth, W, Nick, AM, Landen, CN, Wong, KK, Gray, MJ, Coleman, RL, Bodurka, DC, Brinkley, WR & Sood, AK 2008, Clinical Cancer Research, vol. 14, no. 17, pp. 5437-5446. https://doi.org/10.1158/1078-0432.CCR-07-4922

HLA class i antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma
Han, L, Fletcher, MS, Urbauer, DL, Mueller, P, Landen, CN, Kamat, AA, Lin, YG, Merritt, WM, Spannuth, WA, Deavers, MT, De Geest, K, Gershenson, DM, Lutgendorf, SK, Ferrone, S & Sood, AK 2008, , Clinical Cancer Research, vol. 14, no. 11, pp. 3372-3379. https://doi.org/10.1158/1078-0432.CCR-07-4433

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth
Merritt, WM, Lin, YG, Spannuth, WA, Fletcher, MS, Kamat, AA, Han, LY, Landen, CN, Jennings, N, De Geest, K, Langley, RR, Villares, G, Sanguino, A, Lutgendorf, SK, Lopez-Berestein, G, Bar-Eli, MM & Sood, AK 2008, , Journal of the National Cancer Institute, vol. 100, no. 5, pp. 359-372. https://doi.org/10.1093/jnci/djn024


  • English
  • Hindi